secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0001558370-23-003309
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema reports FY2022 net loss of $104.8M, restructures to focus on OP-1250 Phase 3
--------------------------------------------------------------------------------

- Net loss of $104.8M for FY2022, vs $71.1M in FY2021.
- Cash and securities $204.4M at Dec 31, 2022, expected to fund operations into 2025.
- Workforce reduced by ~25% to focus on late-stage development of OP-1250; CBO leaving, CRO stepping down from role.
- Initiating first pivotal Phase 3 trial of OP-1250 in 2H 2023 for ER+/HER2- metastatic breast cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000155837023003309/0001558370-23-003309-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000155837023003309/olma-20230309x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-003309

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer